$2.72
8.17% today
NYSE, Apr 02, 09:20 pm CET
ISIN
US00445A1007
Symbol
SLRN
Sector
Industry

ACELYRIN Stock price

$2.51
-0.18 6.69% 1M
-2.58 50.69% 6M
-0.63 20.06% YTD
-4.15 62.31% 1Y
-15.49 86.06% 3Y
-15.49 86.06% 5Y
-15.49 86.06% 10Y
NYSE, Closing price Tue, Apr 01 2025
+0.04 1.62%
ISIN
US00445A1007
Symbol
SLRN
Sector
Industry

Key metrics

Market capitalization $252.78m
Enterprise Value $-188.83m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.62
P/B ratio (TTM) P/B ratio 0.55
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-304.86m
Free Cash Flow (TTM) Free Cash Flow $-305.17m
Cash position $447.88m
EPS (TTM) EPS $-2.50
P/E forward negative
Short interest 5.05%
Show more

Is ACELYRIN a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

ACELYRIN Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a ACELYRIN forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a ACELYRIN forecast:

Buy
100%

Financial data from ACELYRIN

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.42 0.42
223% 223%
-
-0.42 -0.42
223% 223%
-
- Selling and Administrative Expenses 66 66
4% 4%
-
- Research and Development Expense 238 238
3% 3%
-
-304 -304
4% 4%
-
- Depreciation and Amortization 0.42 0.42
223% 223%
-
EBIT (Operating Income) EBIT -305 -305
4% 4%
-
Net Profit -248 -248
35% 35%
-

In millions USD.

Don't miss a Thing! We will send you all news about ACELYRIN directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ACELYRIN Stock News

Neutral
GlobeNewsWire
20 days ago
LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners' continued rapid accumulation of 8.8% of ACELYRIN'S outstanding common stock, its Board of Directors has approved the adopt...
Neutral
GlobeNewsWire
29 days ago
Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC.
Neutral
GlobeNewsWire
29 days ago
All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, after due consideration in consultation with its independent financial and...
More ACELYRIN News

Company Profile

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.

Head office United States
CEO Mina Kim
Employees 83
Founded 2020
Website www.acelyrin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today